643
Views
0
CrossRef citations to date
0
Altmetric
This article refers to:
Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations

Correction to: Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations

Grinyó JM, Petruzzelli S. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. Expert Rev Clin Immunol 2014;10(12):1567-79.

Following publication of this article, errors have been identified in the article. These are listed below:

1. Page 1569, Legend for Figure 2: “absorption” should be changed to “dissolution.” “Depiction of the absorption of MeltDose formulation of tacrolimus throughout the gastrointestinal tract across 24 h.” should be “Depiction of the dissolution of MeltDose formulation of tacrolimus throughout the gastrointestinal tract across 24 h.”

2. Page 1569: The references for the sentence “Clinical data show that LCP-Tacro is associated with rapid and consistent exposure (AUC), with lower total daily tacrolimus dose in both kidney and liver transplant recipients who were converted from twice-daily tacrolimus capsules to once-daily prolonged release MeltDose tacrolimus tablets [35,45]” should be 35 & 43 (not 35 & 45).

3. Page 1570 Figure 3B legend: “Day 14 – Tacro once-daily” should be “Day 14 – LCP-Tacro once-daily.”

4. Page 1571 Table 1, study design of study 2018: “Randomized, double-blind, double-dummy, multicenter, prospective” should be “Randomized, open-label, multicenter, prospective.”

5. Page 1571: “Study 2011 primarily evaluated the PK of LCP-Tacro tablets pre-conversion, and at days 7 and 14 post-conversion.” should be “Study 2011 primarily evaluated the PK of LCP-Tacro tablets at days 7 and 14 post-conversion, and compared both with pre-conversion PK of Prograf capsules.”

6. Page 1572 Table 2, study design of study 2018: “Randomized, double-blind, double-dummy, multicenter, prospective” should be “Randomized, open-label, multicenter, prospective.”

7. Page 1574 Table 3: The summary of key efficacy results for the pooled analysis should be:

“LCP-Tacro: 51 (11.9%)

Prograf: 58 (13.4%)

Difference (95% CI) -1.48% (-5.95%, 2.99%), p = 0.54”

(the numbers currently in the table reflect the results for the Black subgroup).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.